Fulcrum Therapeutics (FULC) Cash from Investing Activities (2018 - 2026)

Fulcrum Therapeutics (FULC) has reported Cash from Investing Activities for 9 consecutive years, with $13.8 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash from Investing Activities fell 1.11% year-over-year to $13.8 million; the TTM figure through Jun 2026 stood at -$96.9 million (down 590.07% YoY), while the FY2025 annual figure was $30.7 million, down 4.69% from the prior year.
• Cash from Investing Activities improved to $13.8 million in Q2 2026 per FULC's latest filing, from -$128.2 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $38.1 million in Q1 2024 and bottomed at -$128.2 million in Q1 2026.
• Historically, Cash from Investing Activities has averaged -$4.2 million across 5 years, with a median of $9.1 million in 2024.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities surged 934.58% — and 2026, when it tumbled 16400.64%.
• Fulcrum Therapeutics' Cash from Investing Activities stood at -$36.4 million in 2022, then jumped by 150.48% to $18.4 million in 2023, then slumped by 87.69% to $2.3 million in 2024, then plunged by 146.42% to -$1.0 million in 2025, then surged by 1413.54% to $13.8 million in 2026.
• Business Quant data shows FULC's Cash from Investing Activities at $13.8 million in Q2 2026, -$128.2 million in Q1 2026, and -$1.0 million in Q4 2025.